Lena Lenhammar
Forskningsingenjör vid Institutionen för medicinska vetenskaper; Cancerfarmakologi och beräkningsmedicin
- Telefon:
- 018-611 49 30
- E-post:
- Lena.Lenhammar@medsci.uu.se
- Besöksadress:
- Akademiska sjukhuset, ingång 61
- Postadress:
- Akademiska sjukhuset, ingång 61
751 85 Uppsala
Publikationer
Senaste publikationer
Ingår i BMC Pharmacology & Toxicology, 2024
- DOI för Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment
- Ladda ner fulltext (pdf) av Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment
Ingår i BMC Cancer, 2023
- DOI för Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death
- Ladda ner fulltext (pdf) av Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death
Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway
Ingår i Scientific Reports, 2020
- DOI för Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway
- Ladda ner fulltext (pdf) av Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway
Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition
Ingår i BMC Research Notes, 2019
- DOI för Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition
- Ladda ner fulltext (pdf) av Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition
Ingår i Bioorganic & Medicinal Chemistry, s. 897-911, 2017
- DOI för Design, synthesis and in vitro biological evaluation of oligopeptides targeting E. coli type I signal peptidase (LepB)
- Ladda ner fulltext (pdf) av Design, synthesis and in vitro biological evaluation of oligopeptides targeting E. coli type I signal peptidase (LepB)
Alla publikationer
Artiklar i tidskrift
Ingår i BMC Pharmacology & Toxicology, 2024
- DOI för Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment
- Ladda ner fulltext (pdf) av Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment
Ingår i BMC Cancer, 2023
- DOI för Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death
- Ladda ner fulltext (pdf) av Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death
Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway
Ingår i Scientific Reports, 2020
- DOI för Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway
- Ladda ner fulltext (pdf) av Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway
Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition
Ingår i BMC Research Notes, 2019
- DOI för Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition
- Ladda ner fulltext (pdf) av Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition
Ingår i Bioorganic & Medicinal Chemistry, s. 897-911, 2017
- DOI för Design, synthesis and in vitro biological evaluation of oligopeptides targeting E. coli type I signal peptidase (LepB)
- Ladda ner fulltext (pdf) av Design, synthesis and in vitro biological evaluation of oligopeptides targeting E. coli type I signal peptidase (LepB)
Ingår i Immunopharmacology and immunotoxicology, s. 199-210, 2017